The global cardiovascular biomarker testing market accounted for US$ 6.9 Bn in 2020 with a considerable CAGR of 8.5% during the forecast period of 2021 to 2028.
Report coverage
| Market |
Cardiovascular Biomarker Testing Market |
| Analysis Period |
2017 - 2028 |
| Base Year |
2020 |
| Forecast Data |
2021 - 2028 |
| Segments Covered |
By Biomarker Type, By Disease Type, By End-User, and By Geography |
| Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled |
Becton, Dickinson and Company, Abbott Laboratories, Bio-Rad Laboratories, Inc., BioMérieux, F. Hoffmann-La Roche AG, Danaher Corporation, Randox Laboratories, Thermo Fisher Scientific. And Siemens Healthineers, among others
|
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
| Customization Scope |
10 hrs of free customization and expert consultation
|
When the heart is damaged or strained, molecules called cardiac biomarkers are released into the bloodstream. Measurements of the biomarkers are useful for determining number of cardiovascular and heart related disorders such as cardiac ischemia, acute coronary syndrome, myocardial infarction, etc. Cardiac biomarker tests can also be used to evaluate a person's risk of developing these illnesses, as well as to observe and manage patients who have been already diagnosed with cardiac disorders. Heart biomarker tests are ordered to help diagnose and assess the severity of cardiac ischemia and acute coronary syndrome. Presence of one or more markers in the blood can help identify the disease and severity of the same, allowing a quick and precise diagnosis and treatment.
Market Drivers
Growing burden of Cardiovascular Diseases (CVDs) around the world
CVDs have a high prevalence rate worldwide and account for most number of deaths globally, with more than 17.9 million lives succumbing to CVD every year. Cerebrovascular diseases, coronary heart disorders, rheumatic heart disorders and other heart and blood vessel problems are terms of cardiovascular diseases. Strokes and heart attacks claim 4 out 5 deaths due to CVD, with one-third deaths occurring before the age of 70. According to a report published in the Journal of the American College of Cardiology that studied the enormity of cardiovascular diseases and tendency over the last 30 years globally, the number of people dying from CVD is steadily rising, accounting for one-third of all deaths globally in 2019. The results emphasize the urgent need of cost-effective preventive measures aimed at lowering CVD risk by the countries. The findings suggest that the CVD prevalence surge twice-fold between the periods of 1990 to 2019 from 271 million to 523 million respectively, while the mortality rate too increased gradually during the same period from 12.1 million to 18.6 million. Ischemic heart disease and stroke accounted for the majority of CVD deaths worldwide in 2019, a trend that has been increasing steadily since 1990. The most common risk factors identified are sedentary lifestyle, unhealthy and untimely diet, limited physical activity and increased consumption of alcohol and tobacco. These factors have direct or indirect effect on the person’s blood pressure, lipids, and blood glucose level resulting in overweight and obesity which ultimately leads to more severe and prolonged complications such as heart diseases, strokes and heart failures among others.
COVID-19 Impact
The COVID-19 pandemic is an once-in-a-lifetime global public health challenge that is expected to benefit the cardiovascular diagnostic testing market. Aside from the lungs, this infectious disease has serious consequences for the cardiovascular system, which contributes to the market's positive impact. COVID-19 appears to promote the development of cardiovascular disorders like myocardial infarction, arrhythmias, and acute coronary syndrome. Furthermore, patients with pre-existing co-morbidities and heart problems if happen to contract COVID-19 infection are more likely to have a heart attack or develop congestive heart failure. Furthermore, coronavirus infection is said to affect the endothelial lining of arteries and vein resulting in the inflammation of blood vessels and in some cases even damage of cells and clot formations. This results in the improper blood flow to the heart and other parts of the body leading to severe damage to the vital organs of the body. Thus, the pandemic of COVID-19 has emphasized the importance of dependable diagnostic tests and the rapid progress of novel assays.
Market Segmentation
The cardiovascular biomarker testing market is segmented on the biomarker type, disease type and end-user type. Based on the biomarker type, the market is segmented as kinase, troponins, myoglobin, ischemia modified albumin, high-sensitivity c-reactive protein (hscrp), others. The troponins test segment held the largest share in the market and expected to continue to its dominance during the forecast period. Troponin tests are used to detect heart injury by measuring the level of cardiac-specific troponin in the blood. Troponin is released into the bloodstream when heart muscle cells are damaged. Troponin tests are used to determine whether or not a person has had a heart attack. High level of accuracy and precision of this test helps it dominate the biomarker type segment. In terms of disease type, the market is segmented as congestive heart failure, acute coronary syndrome, myocardial infarction, atherosclerosis, ischemia. Myocardial infarction accounted for the maximum share in the market in terms of disease type. High incidence of the disease is the major reason for the growth of the segment.
Regional Overview
North America accounts for the dominant share in the market in 2020
North America accounted for the maximum share in the global cardiovascular biomarker testing market driven by developed healthcare scenario in the US. The US holds the lion’s share in the North America market owing to high prevalence of cardiovascular diseases in the country. In US, heart disease is the most common cause of death in people of all ethnicity. The Centers for Disease Control and Prevention (CDC) estimates that 1 person dies every 36 seconds due to CVD in the US and approximately 0.65 million people succumb to heart disease each year. Apart from high prevalence, the country boasts a sophisticated healthcare infrastructure and high awareness towards CVD and other diseases, making CVD biomarkers necessary tests in the routine check-ups.
Competitive Landscape
The prominent players operating in the global cardiovascular biomarker testing market include Becton, Dickinson and Company, Abbott Laboratories, Bio-Rad Laboratories, Inc., BioMérieux, F. Hoffmann-La Roche AG, Danaher Corporation, Randox Laboratories, Thermo Fisher Scientific. And Siemens Healthineers, among others
Market Segmentation
Market By Biomarker Type
- Creatine Kinase
- Troponins
- Myoglobin
- Ischemia Modified Albumin
- High-sensitivity C-reactive protein (hsCRP)
- Others
Market By Disease Type
- Congestive Heart Failure
- Acute Coronary Syndrome
- Myocardial Infarction
- Atherosclerosis
- Ischemia
Market By End-User
- Laboratory Testing
- Point of Care Testing
Market By Geography
- North America
- Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Cardiovascular Biomarker Testing
1.1. Definition and Scope
1.1.1. Definition of Cardiovascular Biomarker Testing
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Cardiovascular Biomarker Testing
1.2. Summary
1.2.1. Executive Summary
1.2.2. Cardiovascular Biomarker Testing By Biomarker Type
1.2.3. Cardiovascular Biomarker Testing By Disease Type
1.2.4. Cardiovascular Biomarker Testing By End-User
1.2.5. Cardiovascular Biomarker Testing by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Cardiovascular Biomarker Testing
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Cardiovascular Biomarker Testing
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2019
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Cardiovascular Biomarker Testing By Biomarker Type
4.1. Introduction
4.2. Cardiovascular Biomarker Testing Revenue By Biomarker Type
4.2.1. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast, By Biomarker Type, 2017-2028
4.2.2. Creatine Kinase
4.2.2.1. Creatine Kinase Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.3. Troponins
4.2.3.1. Troponins Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.4. Myoglobin
4.2.4.1. Myoglobin Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.5. Ischemia Modified Albumin
4.2.5.1. Ischemia Modified Albumin Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.6. High-sensitivity C-reactive protein (hsCRP)
4.2.6.1. High-sensitivity C-reactive protein (hsCRP) Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
4.2.7. Others
4.2.7.1. Others Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
CHAPTER 5. Cardiovascular Biomarker Testing Revenue By End-User
5.1. Introduction
5.2. Cardiovascular Biomarker Testing Revenue (US$ Bn) By End-User
5.2.1. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
5.2.2. Laboratory Testing
5.2.2.1. Laboratory Testing Revenue (US$ Bn) and Growth Rate (%), 2017-2028
5.2.3. Point of Care Testing
5.2.3.1. Point of Care Testing Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
CHAPTER 6. Cardiovascular Biomarker Testing By Disease Type
6.1. Introduction
6.2. Cardiovascular Biomarker Testing Revenue (US$ Bn) By Disease Type
6.2.1. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
6.2.2. Congestive Heart Failure
6.2.2.1. Congestive Heart Failure Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
6.2.3. Acute Coronary Syndrome
6.2.3.1. Acute Coronary Syndrome Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
6.2.4. Myocardial Infarction
6.2.4.1. Myocardial Infarction Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
6.2.5. Atherosclerosis
6.2.5.1. Atherosclerosis Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
6.2.6. Ischemia
6.2.6.1. Ischemia Market Revenue (US$ Bn) and Growth Rate (%), 2017-2028
CHAPTER 7. North America Cardiovascular Biomarker Testing By Country
7.1. North America Cardiovascular Biomarker Testing Overview
7.2. U.S.
7.2.1. U.S. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
7.2.2. U.S. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
7.2.3. U.S. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
7.3. Canada
7.3.1. Canada Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
7.3.2. Canada Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
7.3.3. Canada Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
7.4. North America PEST Analysis
CHAPTER 8. Europe Cardiovascular Biomarker Testing By Country
8.1. Europe Cardiovascular Biomarker Testing Overview
8.2. U.K.
8.2.1. U.K. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
8.2.2. U.K. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
8.2.3. U.K. Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
8.3. Germany
8.3.1. Germany Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
8.3.2. Germany Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
8.3.3. Germany Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
8.4. France
8.4.1. France Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
8.4.2. France Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
8.4.3. France Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
8.5. Spain
8.5.1. Spain Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
8.5.2. Spain Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
8.5.3. Spain Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
8.6. Rest of Europe
8.6.1. Rest of Europe Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
8.6.2. Rest of Europe Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
8.6.3. Rest of Europe Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Cardiovascular Biomarker Testing By Country
9.1. Asia Pacific Cardiovascular Biomarker Testing Overview
9.2. China
9.2.1. China Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
9.2.2. China Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
9.2.3. China Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.3. Japan
9.3.1. Japan Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
9.3.2. Japan Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
9.3.3. Japan Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.4. India
9.4.1. India Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
9.4.2. India Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
9.4.3. India Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.5. Australia
9.5.1. Australia Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
9.5.2. Australia Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
9.5.3. Australia Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.6. South Korea
9.6.1. South Korea Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
9.6.2. South Korea Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
9.6.3. South Korea Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
9.7.2. Rest of Asia-Pacific Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
9.7.3. Rest of Asia-Pacific Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Cardiovascular Biomarker Testing By Country
10.1. Latin America Cardiovascular Biomarker Testing Overview
10.2. Brazil
10.2.1. Brazil Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
10.2.2. Brazil Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
10.2.3. Brazil Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
10.3. Mexico
10.3.1. Mexico Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
10.3.2. Mexico Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
10.3.3. Mexico Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
10.4. Rest of Latin America
10.4.1. Rest of Latin America Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
10.4.2. Rest of Latin America Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
10.4.3. Rest of Latin America Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Cardiovascular Biomarker Testing By Country
11.1. Middle East & Africa Cardiovascular Biomarker Testing Overview
11.2. GCC
11.2.1. GCC Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
11.2.2. GCC Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
11.2.3. GCC Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
11.3. South Africa
11.3.1. South Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
11.3.2. South Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
11.3.3. South Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Biomarker Type, 2017-2028
11.4.2. Rest of Middle East & Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By Disease Type, 2017-2028
11.4.3. Rest of Middle East & Africa Cardiovascular Biomarker Testing Revenue (US$ Bn) and Forecast By End-User, 2017-2028
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Cardiovascular Biomarker Testing
12.1. Cardiovascular Biomarker Testing Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Cardiovascular Biomarker Testing
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. COMPANY PROFILE
13.1. Becton, Dickinson and Company
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (US$ Bn), 2019
13.1.3.2. Becton, Dickinson and Company 2019 Cardiovascular Biomarker Testing Business Regional Distribution
13.1.4. Product/ Service and Specification
13.1.5. Recent Developments & Business Strategy
13.2. Abbott Laboratories
13.3. Bio-Rad Laboratories, Inc.
13.4. BioMérieux
13.5. F. Hoffmann-La Roche AG
13.6. Danaher Corporation
13.7. Randox Laboratories
13.8. Thermo Fisher Scientific
13.9. Siemens Healthineers
13.10. Others
